Nykredit A S Invests $20.64 Million in Edwards Lifesciences Corporation $EW

Nykredit A S purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 228,193 shares of the medical research company’s stock, valued at approximately $20,642,000.

Several other institutional investors have also bought and sold shares of EW. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the first quarter worth $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $26,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Citigroup raised their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho upped their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $89.89 on Friday. The stock has a market cap of $51.76 billion, a price-to-earnings ratio of 51.66, a PEG ratio of 2.38 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $89.74 and a 200 day simple moving average of $85.46. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 5,045 shares of company stock worth $457,749. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.